Janus Henderson Group PLC Immuno Gen, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $82.7 Million - $199 Million	-6,640,830 Reduced 37.55%	11,043,986 $327 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $30.8 Million - $43.4 Million	2,185,028 Added 14.1%	17,684,816 $281 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $3.56 Million - $19.1 Million	-950,293 Reduced 5.78%	15,499,788 $292 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $48.8 Million - $65.4 Million	13,302,505 Added 422.63%	16,450,081 $63.2 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $8.36 Million - $11.6 Million	1,837,084 Added 140.18%	3,147,576 $15.6 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $4.88 Million - $7.05 Million	1,090,132 Added 494.71%	1,310,492 $6.27 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $3.21 Million - $5.86 Million	-1,017,967 Reduced 82.21%	220,360 $993,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $3.47 Million - $6.09 Million	814,464 Added 192.15%	1,238,327 $5.89 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $1.92 Million - $3.03 Million	404,198 Added 2055.42%	423,863 $3.14 Million
Q3 2021 Nov 16, 2021	BUY	$5.02 - $6.59 $98,718 - $129,592	19,665 New	19,665 $112,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.